We are committed to providing healthcare professionals with the information and programs that will support their efforts to treat rare, monogenic diseases of the central nervous system.
5 gene therapy candidates for CNS disorders
Foundational collaboration with UT Southwestern
Our gene therapy approach builds upon proven gene therapy platforms
Taysha is accelerating gene therapy research and clinical development across a broad range of monogenic CNS diseases.
For questions about Taysha programs and clinical trials please contact medinfo@tayshagtx.com
Through participation in medical meetings and congresses, we seek to advance the understanding of disease and potential new treatment options. Explore our participation in these events here.
Upcoming Congresses
Past Congresses
Keynote Title: Attracting Capital and Building a Company in the Gene Therapy Space
Presenter: RA Session II, President, CEO and Founder, Taysha Gene Therapies
Session: Emerging Issues in Market Access Keynote Address
Panel Title: Working & Thriving in Industry – What You Need to Know to Prepare and Succeed
Presenter: Steven Gray, Ph.D., Associate Professor, UT Southwestern
Session: Transitioning from Academics to Industry Session
Panel Title: Learning from Experience – Case Studies of Transitions from Academia to Industry
Presenter: Fred Porter, Ph.D., Chief Technical Officer, Taysha Gene Therapies
Session: Transitioning from Academics to Industry
Panel Title: Understanding the Research Process: Being Equipped for Success
Presenter: Steven Gray, Ph.D., Associate Professor, UT Southwestern
Session: Patient Advocates’ Role in Advancing Gene Therapy
Virtual Poster Presentation
Title: Co-creating a gene therapy clinical trial with GM2 gangliosidosis caregivers: A Virtual approach to patient engagement
Presenter: Kristin LaBounty Phillips, Senior Director, Community Engagement, Taysha Gene Therapies
Oral Presentations
Title: A New Approach for Designing a Feedback-Enabled AAV Genome Improves Therapeutic Outcomes of MiniMeCP2 Gene Transfer in Mice Modeling Rett Syndrome (RTT)
Presenter: Sarah E. Sinnett, Ph.D., Assistant Professor, Pediatrics, UT Southwestern Medical Center
Session: AAV Gene Delivery for CNS Disorders
Title: Intrathecal Delivery of Human Bicistronic Hexosaminidase Vector (TGTX-101) to Correct Sandhoff Disease in a Murine Model: A Dosage Study
Presenter: Alex E. Ryckman, Centre for Neuroscience Studies, Queen’s University
Session: Main session, AAV Gene Delivery for CNS Disorders
Title: Direct Vagus Nerve Injection of AAV9 as a Treatment Approach for Autonomic Dysfunction in Giant Axonal Neuropathy
Presenter: Rachel M. Bailey, Ph.D., Assistant Professor, Neuroscience, UT Southwestern Medical Center
Session: New Techniques in Gene Therapy for Neurological Disorders
Poster Presentations
Title: SMRT Sequencing Allows High-Throughput Analysis of a Whole Capsid Shuffled AAV Capsid Library Following CNS Selection in Mice and NHPs
Presenter: Widler Casy, Ph.D., Postdoctoral Researcher, UT Southwestern Medical Center
Session: AAV Vectors – Virology and Vectorology
Title: Gene Replacement Therapy for SURF1-Related Leigh Syndrome Using AAV9
Presenter: Qinglan Ling, Ph.D., Postdoctoral Researcher, UT Southwestern Medical Center
Session: Neurologic Diseases
Title: A Dosage Study to Assess the Long-Term Effects of Gene Therapy for AB-Variant GM2 Gangliosidoses in a Mouse Model Using Adeno-Associated Virus Serotype 9
Presenter: Natalie M. Deschenes, Centre for Neuroscience Studies, Queen’s University
Session: Main Session: Neurologic Diseases
Title: Preclinical Safety and Efficacy of AAV9 Gene Replacement Therapy for SLC6A1 Disorder
Presenter: Frances Shaffo, Ph.D., Postdoctoral Researcher, UT Southwestern Medical Center
Session: Neurologic Diseases
Learn more about our commitment to patients and caregivers living with rare monogenic CNS disease.
Expanded Access, sometimes called Managed Access, Compassionate Use or Early Access, is a potential pathway for a patient with an immediately life-threatening condition, serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
At Taysha, we are collaborating closely with patients, caregivers, patient organizations and medical experts to conduct safe and effective clinical trials. We believe participation in well-designed clinical trials is the most ethical way to determine the safety and efficacy of investigational therapies. Clinical experience from well-controlled trials provide the highest probability of success of bringing an approved therapy to the entire patient community in a safe manner. Hence, Taysha does not offer an Expanded Access Program anywhere in the world.
If you have questions about participating in our clinical trials, please discuss with your health care provider, or contact us at: medinfo@tayshagtx.com.
We reserve the right to revise this policy at any time in accordance with the 21st Century Cures Act.
For questions about programs and clinical trials please contact medinfo@tayshagtx.com.
For questions about programs and clinical trials please contact medinfo@tayshagtx.com.